Association between monocyte Fcγ subclass expression and acute coronary syndrome

Immunity and Ageing

Volumn 1, Issue , 2004, Pages

  Calverley, David C ^a   Varteresian, Taya ^b   Brass, Elizabeth ^b   Tsao Wei, Denice D ^b   Groshen, Susan ^b   Mack, Wendy J ^b   Buchanan, Thomas A ^b   Hodis, Howard N ^b   Schreiber, Alan D ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FC RECEPTOR; FC RECEPTOR 1; FC RECEPTOR 2; FC RECEPTOR 3; OXIDIZED LOW DENSITY LIPOPROTEIN; RECEPTOR SUBTYPE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

EID: 30444453734     PISSN: 17424933     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-4933-1-4     Document Type: Article

References (32)

1. Binder CJ, Chang M.-K, Shaw PX, Miller Y, Vartvigsen K, Dewan A, Witztum JL: Innate and acquired immunity in atherogenesis. Nature and Medicine 2002, 8:1218-1226.
2. Palinski W, Witztum JL: Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Int Med 2000, 247:371-380.
3. Witztum JL, Palinski W: Are immunological mechanisms relevant for the development of atherosclerosis? Clin Immunol 1999, 90:153-156.
4. Hansson GK: Immune mechanisms in atherosclerosis. Arterioscl Thromb Vasc Biol 2001, 21:1876-1890.
5. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL: Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994, 14:32-40.
6. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, Freeman MW: Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002, 277:49982-49988.
7. Lopes-Virella MF, Binzafar N, Rackley S, Takei A, La Via M, Virella G: The uptake of LDL-IC by human macrophages: predominant involvement of the FcγRI receptor. Atherosclerosis 1997, 135:161-170.
8. Khoo JC, Miller E, Pio F, Steinberg D, Witztum JL: Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler Thromb 1992, 12:1258-1266.
9. Griffith RL, Virella GT, Stevenson HC, Lopes-Virella MF: Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med 1988, 168:1041-1059.
10. Klimov AN, Denisenko AD, Popov AV, Nagornev VA, Pleskov VM, Vinogradov AG, Denisenko TV, Magracheva E, Kheifes GM, Kuznetzov AS: Lipoprotein-antibody immune complexes: Their catabolism and role in foam cell formation. Atherosclerosis 1985, 58:1-15.
11. Gisinger C, Virella GT, Lopes-Virella MF: Erythrocyte-bound low density lipoprotein immune complexes lead to cholesteryl ester accumulation in human monocyte-derived macrophages. Clin Immunol Immunopath 1991, 59:37-52.
12. Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King G, Lopes-Virella M, Reusch J, Ruderman N, Steiner G, Vlassara H: Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: Pathogenesis of atherosclerosis in diabetes. 2002, 105:e138-e143.
13. Lopes-Virella MF, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker DJ, Forrest KY: Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 1999, 90:165-172.
14. Powers A: Ch.333: Diabetes mellitus. Harrison's Online 2003 [http://harrisons.accessmedicine.com/harrisons/public/index.html].
15. Semenkovich CF, Heinecke JW: The mystery of diabetes and atherosclerosis: time for a new plot. Diabetes 1997, 46:327-334.
16. Calverley DC, Brass E, Hacker MR, Tsao-Wei DD, Espina BM, Pullarkat VA, Hodis HN, Groshen S: Potential role of platelet FcγRIIA in collagen-mediated platelet activation associated with atherothrombosis. Atherosclerosis 2002, 164:261-267.
17. Calverley DC, Hacker MR, Loda KA, Brass E, Buchanan TA, Tsao-Wei DD, Groshen S: Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus. Br J Haematol 2003, 121:139-142.
18. Watson SP, Asazuma N, Atkinson B, Berlanga D, Best D, Bobe R, Jarvis G, Marshall S, Snell D, Stafford M, Tulasne D, Wilde J, Wonerow P, Frampton J: The role of ITAM- and ITIM-coupled receptors in platelet activation by collagen. Thromb Haemost 2001, 86:276-288.
19. Yanaga F, Poole A, Asselin J, Blake R, Schieven GL, Clark EA, Law CL, Watson SP: Syk interacts with tyrosine-phosphorylated proteins in human platelets activated by collagen and cross-linking of the Fcγ-IIA receptor. Biochem J 1995, 311(Pt 2):471-478.
20. Lusis AJ: Atherosclerosis. Nature 2000, 407:233-241.
21. Kruth HS: Macrophage foam cells and atherosclerosis. Frontiers in Bioscience 2001, 6:D429-D455.
22. Snedecor GW, Cochran WG, Eds: Statistical methods 6th edition. Ames, IA: Iowa State University Press; 1973:271-275.
23. Hughes DA, Fraser IP, Gordon S: Murine macrophage scavenger receptor: in vivo expression and function as receptor for macrophage adhesion in lymphoid and non-lymphoid organs. Eur J Immunol 1995, 25:466-473.
24. Peiser L, Gordon S: The function of scavenger receptors expressed by macrophages and their role in the regulation of inflammation. Microbes and Infection 2001, 3:149-159.
25. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV: FcRγ chain deletion results in pleiotrophic effector cell defects. Cell 1994, 76:519-529.
26. Meuret G, Hoffman G: Monocyte kinetic studies in normal and disease states. Br J Haematol 1973, 24:275-285.
27. Falk E: Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol 1991, 68:28B-35B.
28. Witztum JL: Splenic immunity and atherosclerosis: a glimpse into a novel paradigm? J Clin Invest 2002, 109:721-724.
29. Faggiotto A, Ross R, Harker L: Studies of hypercholesterolemia in the nonhuman primate. I. Changes thst lead to fatty streak formation. Arteriosclerosis 1984, 4:323-340.
30. Tertov VV, Orekhov AN, Sayadyan KS, Serebrennikov SG, Kacharava AG, Lyakishev AA, Smirnov VN: Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture. Atherosclerosis 1990, 81:183-189.
31. Uher F, Lamers MC, Dickler HB: Antigen-antibody complexes bound to B-lymphocyte Fcγ receptors regulate B-lymphocyte differentiation. Cell Immunol 1999, 95:368-379.
32. Kurosaki T, Ravetch JV: A single amino acid in the glycosyl phosphatidylinositol attachment domain determines the membrane topology of FcγRIII. Nature 1989, 342:805-807.